



LKT Laboratories, Inc.

AZD-5363

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A9601

CAS No. 1143532-39-1

Chemical Name

Synonym AZD5363

Formula $C_{21}H_{25}ClN_6O_2$

Formula Wt. 428.92

Melting Point


Purity $\geq 99\%$, $\geq 99\%ee$

Solubility In DMSO(86mg/ml), water
with 2 eq. of acid, insoluble
on ethanol

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description AZD-5363 is an oral pan-AKT inhibitor that causes hyperphosphorylation of AKT, locking it in a catalytically inactive state, unable to phosphorylate downstream signaling substrates such as PRAS40 and GSK-3. This compound displays anticancer chemotherapeutic activity, inhibiting proliferation and inducing tumor regression in in vitro and in vivo models of HER2+ breast cancer and prostate cancer. AZD-5363 may also exhibit inhibitory activity against Rho-associated protein kinase (ROCK), p70S6K, PKA, MKK1, MSK1, MSK2, PKC, PKG, PRKX, and RSK2/3.



Bulk quantities available upon request

Product ID	Size
A9601	1 mg
A9601	5 mg
A9601	25 mg

References Addie M, Ballard P, Buttar D, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. *J Med Chem.* 2013 Mar 14;56(5):2059-73. PMID: 23394218.

Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. *Clin Cancer Res.* 2013 Feb 15;19(4):833-44. PMID: 23258740.

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol Cancer Ther.* 2012 Apr;11(4):873-87. PMID: 22294718.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.